SBIR/STTR Research Award
Development and validation of a sensitive and selective assay for quantitating so
Award amount
$176,145Program and phase
SBIR · Phase IAward year
2014Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Acumen Pharmaceuticals, Inc
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- YHM4FW9X3YC3
- Solicitation number
- PA13-234
- Topic code
- NIA
Research abstract
DESCRIPTION (provided by applicant): In the United States in 2013, 5.2 million people are estimated to suffer from Alzheimer's disease, with as many as 50% being undiagnosed [Alzheimer's Association 2013]. Current diagnostic technologies for Alzheimer's disease are based on the levels of total soluble amyloid beta (Abeta) peptide in plasma and/or cerebrospinal fluid (CSF), levels of tau and phosphorylated tau protein in CSF, or the levels of insoluble amyloid plaques in the brain [e.g., Mulder 2010]. None of the current Alzheimer's disease diagnostic/biomarker technologies detect or quantitate soluble Abeta oligomers. Soluble Abeta oligomers, in contrast to monomeric Abeta or fibrillic Abeta (amyloid plaques), are primary synaptic toxins that cause acute, but reversible, cognitive deficits and the chronic neuronal degeneration of Alzheimer's disease [Walsh 2007, Roychaudhuri 2009, Benilova 2012]. Although the presence of soluble Abeta oligomers in postmortem extracts of human brain tissue is well documented,
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Development of a non-fibrillic amyloid-beta oligomer selective positron emission tomography imaging diagnostic for Alzheimer.
- Biomarker for Alzheimer's Related Cognitive Deficits
- Drug discovery of anti-ADDL therapeutics for Alzheimer's
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Evaluate the Safety, Tolerability, and Immunogenicity of Adjuvanted Preventive Dual Aβ/tau Vaccine, Duvax in Healthy Volunteers
- A Drug Discovery Platform to Prioritize Development of Natural Product Neuromodulators for Treating Cognitive Impairment
- VR-CARES: Feasibility of Virtual Reality for Caregiver Assembly, Relief, Empowerment, and Support to improve social connection, health, and at-home dementia care
- Developing an Integrated Brain State Monitor for Personalized Anesthesia Decision Support: Preventing Postoperative Delirium in Elderly and Patients At Risk for Alzheimer's or Related Dementias
- Lead Optimization of a Therapeutic Candidate for Alzheimer’s Disease
Research funding history
4 SBIR/STTR records share this UEI (2005–2016). Reported award amounts total $727,861. Reported amounts are not federal obligations.
Phases: Phase I
Agencies: Department of Health and Human Services